BioAegis and Prenosis partner for inflammatory disease therapies
Pharmaceutical Business Review
The collaboration will evaluate biomarkers and patient subgroups with improved responses to BioAegis' gelsolin therapy, a critical immune regulatory protein that aims to rebalance inflammation without
pharminent
April 22, 2026 (Last updated: April 22, 2026)
Pharmaceutical Business Review
The collaboration will evaluate biomarkers and patient subgroups with improved responses to BioAegis’ gelsolin therapy, a critical immune regulatory protein that aims to rebalance inflammation without
